S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
NYSE:LH

Laboratory Co. of America (LH) Stock Price, News & Analysis

$218.46
+1.89 (+0.87%)
(As of 03/28/2024 ET)
Today's Range
$215.64
$218.67
50-Day Range
$209.06
$228.11
52-Week Range
$174.20
$234.09
Volume
607,121 shs
Average Volume
747,746 shs
Market Capitalization
$18.37 billion
P/E Ratio
46.78
Dividend Yield
1.32%
Price Target
$243.50

Laboratory Co. of America MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.79 Rating Score
Upside/​Downside
11.5% Upside
$243.50 Price Target
Short Interest
Healthy
2.37% of Float Sold Short
Dividend Strength
Moderate
Based on Four Factors
Sustainability
-0.66
Upright™ Environmental Score
News Sentiment
0.85mentions of Laboratory Co. of America in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$8.82 M Sold Last Quarter
Proj. Earnings Growth
8.12%
From $14.77 to $15.97 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.99 out of 5 stars

Medical Sector

4th out of 938 stocks

Medical Laboratories Industry

1st out of 20 stocks

LH stock logo

About Laboratory Co. of America Stock (NYSE:LH)

Laboratory Corporation of America Holdings operates as a life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Biopharma Laboratory Services (BLS). The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C and vitamin D, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations (MCOs), including health fairs, on-site and at-home testing, vaccinations, and health screenings. In addition, the company offers online and mobile applications that enable patients to check test results; online applications for providers, MCOs, and accountable care organizations; and drug development, medical device, and companion diagnostic development solutions from early-stage research to clinical development, as well as support for crop protection and chemical testing. It serves pharmaceutical, biotechnology, medical device, and diagnostics companies; and MCOs, employer plans, other health insurance providers, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, crop protection and chemical companies, academic institutions, independent clinical laboratories, and retailers. The company was incorporated in 1994 and is headquartered in Burlington, North Carolina.

LH Stock Price History

LH Stock News Headlines

LifeMD Shares Come Back to Life on GLP-1 Business Growth (LH)
LifeMD stock is surging as the company is riding the GLP-1 trend to double-digit revenue growth and projections for 67% earnings growth in 2024
Did You Get Your Free Bitcoin Yet?
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
Labcorp To Acquire Select Assets Of BioReference Health - Quick Facts
Laboratory Co. of America (NYSE:LH) Upgraded to "Buy" at Argus
the most reliable asset on earth is making a comeback
Global tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.
LH Apr 2024 210.000 call
Labcorp (LH) Moves to Buy: Rationale Behind the Upgrade
See More Headlines
Receive LH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Laboratory Co. of America and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/15/2024
Ex-Dividend for 3/13 Dividend
2/26/2024
Dividend Payable
3/13/2024
Today
3/28/2024
Next Earnings (Confirmed)
4/25/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medical laboratories
Sub-Industry
Health Care Services
CUSIP
50540R40
Employees
67,000
Year Founded
1995

Price Target and Rating

Average Stock Price Target
$243.50
High Stock Price Target
$270.00
Low Stock Price Target
$210.00
Potential Upside/Downside
+11.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.79
Research Coverage
14 Analysts

Profitability

Net Income
$418 million
Pretax Margin
4.68%

Debt

Sales & Book Value

Annual Sales
$12.16 billion
Cash Flow
$20.81 per share
Book Value
$92.76 per share

Miscellaneous

Free Float
83,553,000
Market Cap
$18.37 billion
Optionable
Optionable
Beta
1.02

Social Links

10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

Should I Buy Laboratory Co. of America Stock? LH Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Laboratory Co. of America Holdings:

  • Strong institutional investor ownership at 89.37% indicates confidence in the company's future growth potential and stability.
  • Recent acquisitions of shares by reputable investment firms like Mercer Global Advisors Inc. ADV demonstrate positive sentiment towards the company's performance.
  • Analyst ratings such as "outperform" and "overweight" from Leerink Partners and JPMorgan Chase & Co. respectively suggest a favorable outlook for the stock.
  • Operates in two segments, Labcorp Diagnostics and Labcorp Drug Development, diversifying its revenue streams and reducing dependency on a single market.
  • Continuous growth in stake by major institutional investors like BlackRock Inc. and Vanguard Group Inc. indicates long-term confidence in the company's financial health.

Cons

Investors should be bearish about investing in Laboratory Co. of America Holdings for these reasons:

  • Recent downgrade in ratings from "b-" to "c+" by TheStreet may raise concerns about the company's current performance and future prospects.
  • Increased competition in the life sciences industry could potentially impact Laboratory Co. of America's market share and profitability.
  • Fluctuations in the stock price, currently at a certain level, may pose risks for short-term investors seeking quick returns.
  • Market volatility and regulatory changes in the healthcare sector could affect the company's operations and financial results.
  • Potential challenges in maintaining growth momentum and innovation in a rapidly evolving healthcare landscape may impact long-term shareholder value.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, March 26, 2024. Please send any questions or comments about these Laboratory Co. of America pros and cons to contact@marketbeat.com.

LH Stock Analysis - Frequently Asked Questions

Should I buy or sell Laboratory Co. of America stock right now?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Laboratory Co. of America in the last twelve months. There are currently 3 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" LH shares.
View LH analyst ratings
or view top-rated stocks.

What is Laboratory Co. of America's stock price target for 2024?

14 equities research analysts have issued 12 month price targets for Laboratory Co. of America's shares. Their LH share price targets range from $210.00 to $270.00. On average, they anticipate the company's stock price to reach $243.50 in the next year. This suggests a possible upside of 11.5% from the stock's current price.
View analysts price targets for LH
or view top-rated stocks among Wall Street analysts.

How have LH shares performed in 2024?

Laboratory Co. of America's stock was trading at $227.29 at the beginning of 2024. Since then, LH shares have decreased by 3.9% and is now trading at $218.46.
View the best growth stocks for 2024 here
.

Are investors shorting Laboratory Co. of America?

Laboratory Co. of America saw a decline in short interest in the month of February. As of February 29th, there was short interest totaling 2,130,000 shares, a decline of 18.7% from the February 14th total of 2,620,000 shares. Based on an average daily trading volume, of 727,600 shares, the days-to-cover ratio is currently 2.9 days. Approximately 2.5% of the shares of the company are sold short.
View Laboratory Co. of America's Short Interest
.

When is Laboratory Co. of America's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 25th 2024.
View our LH earnings forecast
.

How can I listen to Laboratory Co. of America's earnings call?

Laboratory Co. of America will be holding an earnings conference call on Thursday, April 25th at 9:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Laboratory Co. of America's earnings last quarter?

Laboratory Co. of America Holdings (NYSE:LH) released its quarterly earnings data on Thursday, February, 15th. The medical research company reported $3.30 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.29 by $0.01. The medical research company earned $3.03 billion during the quarter, compared to the consensus estimate of $3.02 billion. Laboratory Co. of America had a trailing twelve-month return on equity of 13.99% and a net margin of 3.24%. The company's revenue was down 17.5% on a year-over-year basis. During the same quarter in the previous year, the company posted $4.14 earnings per share.
Read the conference call transcript
.

How often does Laboratory Co. of America pay dividends? What is the dividend yield for Laboratory Co. of America?

Laboratory Co. of America announced a quarterly dividend on Friday, January 12th. Shareholders of record on Tuesday, February 27th will be given a dividend of $0.72 per share on Wednesday, March 13th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.32%. The ex-dividend date of this dividend is Monday, February 26th.
Read our dividend analysis for LH
.

Is Laboratory Co. of America a good dividend stock?

Laboratory Co. of America (NYSE:LH) pays an annual dividend of $2.88 per share and currently has a dividend yield of 1.35%. The dividend payout ratio is 61.67%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, LH will have a dividend payout ratio of 18.03% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for LH.

What guidance has Laboratory Co. of America issued on next quarter's earnings?

Laboratory Co. of America issued an update on its FY 2024 earnings guidance on Friday, February, 16th. The company provided EPS guidance of 14.300-15.400 for the period, compared to the consensus estimate of 14.600. The company issued revenue guidance of $12.7 billion-$13.0 billion, compared to the consensus revenue estimate of $12.6 billion.

What is Adam Schechter's approval rating as Laboratory Co. of America's CEO?

143 employees have rated Laboratory Co. of America Chief Executive Officer Adam Schechter on Glassdoor.com. Adam Schechter has an approval rating of 73% among the company's employees.

What other stocks do shareholders of Laboratory Co. of America own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Laboratory Co. of America investors own include Gilead Sciences (GILD), Micron Technology (MU), Intel (INTC), Pfizer (PFE), Johnson & Johnson (JNJ), NVIDIA (NVDA), Abbott Laboratories (abt), AbbVie (ABBV), Alibaba Group (BABA) and Amgen (AMGN).

Who are Laboratory Co. of America's major shareholders?

Laboratory Co. of America's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (11.48%), Vanguard Group Inc. (11.59%), Wellington Management Group LLP (2.67%), Dimensional Fund Advisors LP (1.70%), Norges Bank (1.51%) and Northern Trust Corp (1.37%). Insiders that own company stock include Amy B Summy, Brian J Caveney, Der Vaart Sandra D Van, Dwight Gary Gilliland, Glenn A Eisenberg, Jean-Luc Belingard, Jonathan P Divincenzo, Kerrii B Anderson, Mark S Schroeder, Paul R Kirchgraber, Peter J Wilkinson, Peter M Neupert and R Sanders Williams.
View institutional ownership trends
.

How do I buy shares of Laboratory Co. of America?

Shares of LH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Laboratory Co. of America have any subsidiaries?
The following companies are subsidiares of Laboratory Co. of America: 1957285 Ontario Inc. dba Quality Underwriting Services, 2089729 Ontario Inc., 2248848 Ontario Inc., 3065619 Nova Scotia Company, 3257959 Nova Scotia Company, 8165335 Canada Inc., 8348596 Canada Inc., 896988 Ontario Limited, 9279-3280 Quebec Inc., Accupath Diagnostic Laboratories Inc., Assets of Pathology Inc, Beacon LBS IPA Inc., Beacon Laboratory Benefit Solutions Inc., CannAmm GP Inc., CannAmm Limited Partnership, Center for Disease Detection International, Center for Disease Detection LLC, Centrex Clinical Laboratories Inc., Chiltern, Clearstone Central Laboratories (U.S.) Inc., Clearstone Holdings (International) Ltd., Clinical Outreach Laboratory Services, Clipper Holdings Inc., Colorado Coagulation Consultants Inc., Colorado Laboratory Services LLC, Correlagen Diagnostics Inc., Covance Inc., Curalab Inc., Cytometry Associates Inc., Czura Thornton (Hong Kong) Limited, DCL Acquisition Inc., DCL Medical Laboratories LLC, DCL Sub LLC, DIANON Systems Inc., DL Holdings Limited Partnership, Decision Diagnostics L.L.C. (aka DaVinici/Medicorp LLC), Diagnostic Services Inc., DynaLifeDX, Dynacare - Gamma Laboratory Partnership, Dynacare Company, Dynacare G.P. Inc., Dynacare Holdco LLC, Dynacare Laboratories Inc., Dynacare Laboratories Limited Partnership, Dynacare Northwest Inc., Dynacare Realty Inc., DynalifeDX Infrastructure Inc., Envigo's nonclinical contract research services business, Esoterix Genetic Counseling LLC, Esoterix Genetic Laboratories LLC, Esoterix Inc., Execmed Health Services Inc., FirstSource Laboratory Solutions Inc., GDML Medical Laboratories Inc, Gamma Dynacare Central Medical Laboratories GP Inc., Gamma Dynacare Central Medical Laboratory Limited Partnership, HHLA Lab-In-An-Envelope LLC, Health Testing Centers Inc., Health Trans Services Inc., Home Healthcare Laboratory of America LLC, IDX Pathology Inc., Impact Genetics Corporation, Impact Genetics Inc., Kaleida LabCorp LLC, Lab Delivery Service of New York City Inc., LabCorp BVBA, LabCorp Belgium Holdings Inc., LabCorp Central Laboratories (Canada) Inc., LabCorp Central Laboratories (China) Inc., LabCorp Colorado Inc., LabCorp Development Company, LabCorp Employer Services Inc., LabCorp Health System Diagnostics LLC, LabCorp Indiana Inc., LabCorp Japan G.K., LabCorp Limited, LabCorp Michigan Inc., LabCorp Nebraska Inc., LabCorp Neon Ltd., LabCorp Neon Switzerland S.à.r.l., LabCorp Specialty Testing Billing Service Inc., LabCorp Specialty Testing Group Inc., LabCorp Staffing Solutions Inc., LabCorp Tennessee LLC, LabCorp UK Holdings Ltd., LabWest Inc., Laboratoire Bio-Medic Inc., Laboratory Corporation of America, Lifecodes Corporation, LipoScience Inc., Litholink Corporation, MEDTOX Scientific Inc., MNG Laboratories, MedAxio Insurance Medical Services GP Inc., MedAxio Insurance Medical Services LP, Medical Neurogenitics LLC, Medtox Diagnostics Inc., Medtox Laboratories Inc., Monogram Biosciences Inc., Monogram Biosciences UK Limited, Myriad Autoimmune’s Vectra Testing Business, NWT Inc., National Genetics Institute, New Brighton Business Center LLC, New Imaging Diagnostics LLC, New Molecular Diagnostics Ventures LLC, Orchid Cellmark ULC, Ovia Health, PA Labs Inc., Paclab LLC, Path Lab Incorporated, Pathology Associates Medical Lab LLC, Pee Dee Pathology Associates Inc., Personal Genome Diagnostics Inc., Persys Technology Inc., Pixel by LabCorp, Princeton Diagnostic Laboratories of America Inc., Protedyne Corporation, SW/DL LLC, Saint Josephs-PAML LLC, Sequenom Biosciences (India) Pvt. Ltd., Sequenom Inc, Sequenom Inc., Tandem Labs Inc., Toxikon Corporation, Tri-Cities Laboratory LLC, Viro-Med Laboratories Inc., Visiun, and Yakima Medical Arts Inc..
Read More
This page (NYSE:LH) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners